Advertisement
Screener

CERO THERAPEUTICS HOLDINGS, INC. (CERO) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

CERO THERAPEUTICS HOLDINGS, INC. Stock-Based Compensation

CERO THERAPEUTICS HOLDINGS, INC. (CERO) reported Stock-Based Compensation of $2.74 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-08-14

  • 2026-06-30: Share-based Payment Arrangement, Noncash Expense 6 month $2.74M.
  • 2025-06-30: Share-based Payment Arrangement, Noncash Expense 6 month $488.27K.
Period endShare-based Payment Arrangement, Noncash Expense 6 month
2026-06-30$2.74M
10-Q · filed 2026-08-14
2025-06-30$488.27K
10-Q · filed 2026-08-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
AIM ImmunoTech Inc. (AIM)United States$0.006B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
VivoSim Labs, INC. (VIVS)United States$0.003B
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
IN8BIO, INC. (INAB)United States$0.012B-0.76
CURIS INC (CRIS)United States$0.002B-0.05